
Adagene Investor Relations Material
Latest events

Q4 2024
24 Mar, 2025

Q2 2024
25 Jul, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adagene Inc
Access all reports
Adagene Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company utilizes its proprietary technology platforms, including its Dynamic Precision Library (DPL) and SAFEbody technology, to engineer therapeutic antibodies with unique functional epitopes. These technologies enable the development of innovative monoclonal antibodies that target various cancers, aiming to improve both safety and efficacy. Adagene's product pipeline includes several candidates in various stages of clinical and preclinical development. The company is actively engaged in both mono and combination therapies, exploring new approaches to treat solid tumors and other cancer types.The company is headquartered in Suzhou, China, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ADAG
Country
🇺🇸 United States